Beximco Pharma revenue crosses Tk5,000cr for first time, profit jumps 31%

Beximco Pharmaceuticals’ revenue crossed Tk5,000 crore for the first time in FY26, rising 15% year-on-year to Tk5,626 crore as growth in domestic sales and exports boosted earnings.

According to the pharma giant’s audited financial statements, net profit increased 31% to Tk914 crore, while earnings per share (EPS) stood at Tk20.17. Its board recommended a 60% cash dividend for the financial year.

Domestic sales, which account for the bulk of its business, grew 15% to Tk5,164 crore. Export revenue rose 8% to Tk441 crore, reflecting continued expansion in international markets.

The performance puts Beximco Pharma second among listed pharmaceutical companies in Bangladesh in both revenue and profit, behind Square Pharmaceuticals. According to IQVIA data, Beximco Pharma ranks third among the country’s pharmaceutical companies, followed by Square and Incepta.  

Square Pharma reported FY26 revenue of Tk8,606 crore and profit of Tk2,770 crore. Beximco Pharma followed with Tk5,626 crore in revenue and Tk914 crore in profit. Renata posted revenue of Tk4,620 crore and profit of Tk364 crore, while Acme Laboratories recorded Tk4,159 crore in revenue and Tk268 crore in profit. Beacon Pharma reported revenue of Tk1,642 crore and profit of Tk194 crore.

In a statement published on the London Stock Exchange, Beximco Pharma Managing Director Iqbal Ahmed said the company had maintained double-digit revenue growth despite a challenging macroeconomic environment.

He attributed the performance to operational execution, a stronger product portfolio and expansion in domestic and international markets, adding that the company remained focused on its strategy amid global economic challenges.

A major development during the year was the launch of Triko, which the company describes as the world’s first and only generic copy of the cystic fibrosis drug Trikafta. The medicine aims to make the treatment accessible to patients at a fraction of the originator product’s price.

The company said it had handed over the medicine to patients in six countries.

During FY26, Beximco Pharma launched eight generic medicines in 19 presentations in Bangladesh, including two products introduced in the country for the first time. It also secured 43 new registrations for 36 products across 18 countries.

The company expanded its international presence by launching Eletriptan tablets for migraine treatment in the US and Sotalol tablets in Canada. It also began exporting to Lebanon.

After the financial year, Beximco Pharma launched another five generic medicines in six presentations in Bangladesh, including two first-time introductions. It also completed nine registrations for eight products across six countries.

The company was also nominated for the Scrip Awards 2026 in the Community Partnership of the Year category.

Meanwhile, Beximco Pharma’s board is set to undergo restructuring following an agreement with the Bangladesh Securities and Exchange Commission (BSEC) on its proposed reconstitution.

Under the agreement reached on 30 September, the board will comprise nine members: three sponsor representatives, a new managing director, an IFIC Bank representative and four independent directors. The arrangement is conditional on the withdrawal and disposal of the company’s two writ petitions challenging the BSEC order.

Iqbal Ahmed will step down as managing director but remain a director. Vice-Chairman Salman F Rahman and directors A B Siddiqur Rahman and Reem H Shamsuddoha will also leave the board.

Following the decision, A B Siddiqur Rahman and Reem H Shamsuddoha resigned from the company’s board.

Beximco Pharma shares closed 0.21% higher at Tk144.50 on the Dhaka Stock Exchange today (11 November), giving the company a market capitalisation of Tk6,432 crore.

According to its September shareholding report, sponsors and directors held 30.13% of the company’s shares, institutional investors 25.73%, foreign investors 26.96% and the public the remaining 17.12%.